Company IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 02:59:59 2026-02-10 EST			5-day change	1st Jan Change
10.25 ^GBX	0.00%		0.00%	-12.77%

02-05	Ixico Names Chief Commercial Officer	MT
02-05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI

Business description: IXICO plc

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

Number of employees: 79

Sales by Activity: IXICO plc

Fiscal Period: September	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)	2025 (GBP)
Medical Labs & Research	9.19M	8.64M	6.66M	5.77M	6.53M

See all business segments

Geographical breakdown of sales: IXICO plc

Fiscal Period: September	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)	2025 (GBP)
United States of America	1.86M	2.71M	3.05M	2.36M	2.87M
United Kingdom	1.98M	2.06M	952K	1.33M	1.79M
Netherlands	1.25M	436K	862K	742K	623K
Denmark	-	-	-	-	407K
Switzerland	3.25M	2.08M	816K	500K	398K
Ireland	482K	724K	689K	557K	304K
Other - Europe	370K	638K	293K	272K	136K
Rest of World	-	-	-	-	6K

See all geographic segments

Executive Committee: IXICO plc

Manager	Title	Age	Since
Bram Goorden CEO	Chief Executive Officer	53	2024-08-18
Grant Nash DFI	Director of Finance/CFO	50	2019-08-20
Robin Wolz CTO	Chief Tech/Sci/R&D Officer	-	2020-12-31
James Chandler PRN	Corporate Officer/Principal	-	2025-05-31

See IXICO PLC governance

Composition of the Board of Directors: IXICO plc

Director	Title	Age	Since
Mark Warne CHM	Chairman	50	-
Grant Nash BRD	Director/Board Member	50	2019-08-20
Katherine Rogers BRD	Director/Board Member	60	2022-01-20
Dipti Amin BRD	Director/Board Member	62	2023-10-04
Bram Goorden BRD	Director/Board Member	53	2024-08-18

Composition of the Board of Directors

Shareholders: IXICO plc

Name	Equities	%	Valuation
Gresham House Asset Management Ltd. 17.4 %	16,120,584	17.4 %	2 M p
BGF Investment Management Ltd. 13.91 %	12,887,000	13.91 %	2 M p
Octopus Investments Ltd. 10.69 %	9,902,257	10.69 %	2 M p
Maven Capital Partners UK LLP 8.721 %	8,081,651	8.721 %	1 M p
Canaccord Genuity Asset Management Ltd. 8.062 %	7,471,000	8.062 %	1 M p

List of IXICO PLC shareholders

Company details: IXICO plc

Ixico Plc

Griffin Court

EC1A 9PN, London

+44 20 3763 7499

http://ixico.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IXICO PLC	0.00%	0.00%	-12.77%	-63.72%	12.98M
LONZA GROUP AG	+1.34%	-0.69%	-14.38%	-4.64%	47.17B
BEONE MEDICINES AG	-1.43%	+1.12%	+56.09%	+40.18%	38.6B
CELLTRION, INC.	+4.55%	+13.30%	+33.18%	+51.67%	34.53B
IQVIA HOLDINGS INC.	+2.76%	-16.68%	-7.43%	-16.34%	32.68B
REVOLUTION MEDICINES, INC.	-0.77%	-0.43%	+129.30%	+283.13%	18.7B
MEDPACE HOLDINGS, INC.	-2.16%	-9.83%	+49.77%	+135.13%	14.94B
Average	+0.63%	-1.53%	+33.40%	+60.77%	26.66B
Weighted average by Cap.	+1.15%	-1.07%	+29.74%	+53.02%